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Abstract
 
Recent studies with transfected COS-7 cells have shown
that functionally inactive mutant V2 vasopressin receptors
(occurring in patients with nephrogenic diabetes insipidus)
can be functionally rescued by coexpression of a carboxy-
terminal V2 receptor fragment (V2-tail) spanning the re-
gion where various mutations occur [Schöneberg, T., J.
Yun, D. Wenkert, and J. Wess. 1996. 
 
EMBO 
 
(
 
Eur. Mol.
Biol. Organ.
 
) 
 
J.
 
 15:1283–1291]. In this study, we set out to
characterize the underlying molecular mechanism. Using a
coimmunoprecipitation strategy and a newly developed
sandwich ELISA system, a direct and highly specific inter-
action between the mutant V2 vasopressin receptor proteins
and the V2-tail polypeptide was demonstrated. To study the
potential therapeutic usefulness of these findings, Chinese
hamster ovary (CHO) cell lines stably expressing low levels
of functionally inactive mutant V2 vasopressin receptors
were created and infected with a recombinant adenovirus
carrying the V2-tail gene fragment. After adenovirus infec-
tion, vasopressin gained the ability to stimulate cAMP for-
mation with high potency and efficacy in all CHO cell
clones studied. Moreover, adenovirus-mediated gene trans-
fer also proved to be a highly efficient method for achieving
expression of the V2-tail fragment (as well as the wild-type
V2 receptor) in Madin-Darby canine kidney tubular cells.
Taken together, these studies clarify the molecular mecha-
nisms by which receptor fragments can restore function of
mutationally inactivated G protein–coupled receptors and
suggest that adenovirus-mediated expression of receptor
fragments may lead to novel strategies for the treatment of
a variety of human diseases. (
 
J. Clin. Invest.
 
 1997. 100:
1547–1556.) Key words: nephrogenic diabetes insipidus 
 
•
 
vasopressin receptor 
 
• 
 
gene therapy 
 
• 
 
receptor mutagenesis 
 
•
 
receptor folding
 
Introduction
 
It has become clear during the past decade that G protein–
coupled receptors (GPCRs)
 
1
 
 form one of the largest protein
families found in nature (1). Recently, it has been demon-
strated that mutations in distinct GPCRs are responsible for
several hereditary and acquired diseases such as retinitis pig-
mentosa (2), familial male precocious puberty (3), hyperthy-
roidism (4), or X-linked nephrogenic diabetes insipidus (NDI)
(5). Several dozens of different mutations have been identified
in the V2 vasopressin receptor gene of NDI patients (6), mak-
ing the kidneys insensitive to the antidiuretic actions of the
hormone arginine vasopressin (AVP). The vast majority of
these mutations results in single amino acid substitutions (mis-
sense mutations) or receptor truncations caused by nonsense
or frameshift mutations (7).
Based on findings that GPCRs are composed of multiple
folding units (8, 9), we demonstrated recently in transiently
transfected COS-7 cells that mutant V2 vasopressin receptors
containing clinically relevant mutations in the carboxy-termi-
nal third of the receptor protein can be functionally rescued by
coexpression of a nonmutated carboxy-terminal V2 receptor
fragment (V2-tail) (10). To test the hypothesis that this phe-
nomenon is due to a direct interaction between the two
polypeptides, we used here a coimmunoprecipitation and a
newly developed sandwich ELISA strategy. Thus, we could
show that the V2-tail can associate directly with a truncated V2
receptor (E242stop) but not with other classes of GPCRs con-
taining similar mutations.
The second major goal of this study was to test the poten-
tial therapeutic usefulness of this coexpression strategy.
Toward this aim, Chinese hamster ovary (CHO) cell lines ex-
pressing low levels of functionally inactive mutant V2 recep-
tors which more closely mimic the physiological situation were
infected with a recombinant adenovirus carrying the V2-tail
gene fragment. Adenoviral vectors can deliver recombinant
genes efficiently to a great number of diverse cell types, includ-
ing mitotically quiescent cells, and are therefore considered
promising candidates for a number of potential human gene
therapy applications (11, 12). Whereas noninfected CHO cell
lines (expressing mutant V2 receptors) did not show a func-
tional response upon addition of AVP, infection of the individ-
ual CHO cell clones with recombinant V2-tail adenovirus
enabled AVP to induce a pronounced cAMP response. Fur-
thermore, we showed that recombinant adenoviruses can be
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used to achieve efficient expression of the V2-tail fragment
and of the wild-type V2 receptor not only in fibroblasts but
also in Madin-Darby canine kidney (MDCK) tubular cells
as well.
Taken together, our data suggest that adenovirus-mediated
expression of receptor fragments results in cell-specific molec-
ular correction of functional receptor defects, and may lead to
novel strategies in the treatment of diseases caused by inacti-
vating mutations of GPCRs.
 
Methods
 
Construction of mutant V2 vasopressin receptor genes and recombi-
nant adenoviral vectors.
 
Mutant V2 receptors (Fig. 1, 
 
A
 
 and 
 
B
 
) were
created by standard PCR mutagenesis techniques (13), using the hu-
man V2 vasopressin receptor expression plasmid V2-pcD-PS (10) as a
template. In the case of truncated receptors, the coding sequence
downstream of the newly introduced stop codon was partially re-
moved (deletion of 232 bp in E242stop and 106 bp in W284stop). The
wild-type human gonadotropin-releasing hormone (GnRH) receptor
(recloned from the human pituitary by R. Grosse and T. Guder-
mann), rat vasopressin V1a receptor (14), human oxytocin (Ox) re-
ceptor (15), human cholecystokinin type A (CCK
 
A
 
) receptor (16),
and mouse luteinizing hormone (LH) receptor (17) were subcloned
into pcD-PS. In addition, the wild-type and various mutant V2 vaso-
pressin receptors, GnRH receptor, CCK
 
A
 
 receptor, and rat m3 mus-
carinic receptor (9), were tagged with an amino-terminal 9–amino
acid sequence (YPYDVPDYA) (18) derived from the influenza virus
hemagglutinin protein (HA-tag). The identity of the various con-
structs and the correctness of all PCR-derived sequences were con-
firmed by restriction analysis and dideoxy sequencing (19).
Recombinant (E1-deficient) adenoviruses (serotype 5) carrying
the wild-type V2 receptor and the V2-tail polypeptide (Fig. 1 
 
C
 
) were
generated as follows. The coding sequences of the HA-tagged wild-
type V2 receptor and the V2-tail polypeptide, including the non–tis-
sue-specific SV40 early region promoter and SV40 polyadenylation
signal (taken from pcD-PS vector), were inserted into the pdE1sp1B
vector (20) via the EcoRI site present in the polylinker sequence. The
two resulting plasmids were then cotransfected with the pJM17 plas-
mid (21) into subconfluent HEK 293 cells using a modified calcium
phosphate coprecipitation method (22). After plaque isolation, re-
combinant viruses, referred to as Ad-V2 and Ad-V2-tail, were ampli-
fied, and individual virus stocks were analyzed by PCR and restric-
tion analysis.
For preparation of large purified virus stocks, HEK 293 cells were
infected (
 
z
 
 5 pfu/cell) and harvested after cytopathic effects became
Figure 1. V2 vasopressin receptor con-
structs used in this study, and construction 
of recombinant adenoviruses. (A) Trun-
cated (E242stop, W284stop, and Y280C-
R337stop; filled black circles) and full-
length wild-type and mutated V2 receptors 
(Y280C; filled black circles) were tagged 
with a 9–amino acid HA-epitope (filled 
gray circles). (B) Mutant V2-tail constructs 
(point mutations Y280C, L292P and dele-
tion V277del; filled black circles) were cre-
ated by subcloning mutated fragments 
from full-length V2 receptor mutants into 
the V2-tail constructs. (C) Expression cas-
settes of V2-tail and wild-type V2 receptor 
(not shown) were introduced into the 
polylinker site of pDE1sp1B. pJM17 con-
tains the adenovirus type 5 sequence. Ho-
mologous recombination between the two 
plasmids (after cotransfection into 293 
cells) led to the formation of a replication-
deficient recombinant adenovirus contain-
ing the V2-tail (Ad-V2-tail) or wild-type 
V2 receptor (Ad-V2) DNA (not shown). 
Ampr, ampicillin resistance gene. ITR, in-
verted terminal repeat. mu, map units. ori, 
origin. SV40 pro, SV40 early region pro-
moter. SV40 pA, SV40 polyadenylation 
signal.
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visible (48 h). Cells were lysed in PBS containing 0.2% NP-40. After
removing cell debris, the virus suspension was subjected to two CsCl
step gradient centrifugations as described (23). CsCl was removed by
gel filtration through Sephadex G25 columns (Pharmacia Diagnostics
AB, Uppsala, Sweden), and aliquots were stored at 
 
2
 
70
 
8
 
C in storage
buffer containing 150 mM NaCl, 3 mM KCl, 1 mM MgCl
 
2
 
, 10 mM
Tris-HCl (pH 7.4), and 10% glycerol. Titers were determined by
plaque assay in HEK 293 cells.
 
Cell culture and gene transfer.
 
Cells were grown in DMEM (COS-7
and MDCK cells) and Ham’s F12 medium (CHO-K1 cells), supple-
mented with 10% FBS. For transient transfections of COS-7 cells, a
DEAE-dextran method was used (24). In brief, 4 
 
m
 
g plasmid DNA
per 10-cm dish was transfected. To establish CHO-K1 cell lines stably
expressing wild-type or mutant V2 receptors, receptor constructs
were cotransfected with pcDNAneo (Invitrogen Corp., Leek, The
Netherlands) using lipofectamin (Life Technologies, Inc., Eggenstein,
Germany) and a V2 receptor construct to pcDNAneo ratio of 20:1
(4 
 
m
 
g total amount of plasmid DNA). Single colonies resistant to the
antibiotic G418 (700 
 
m
 
g/ml; Life Technologies, Inc.) were isolated
and maintained in Ham’s F12 medium supplemented with G418
(400 
 
m
 
g/ml). Adenoviral infections were carried out in petri dishes
containing cell monolayers at 90% confluency. The appropriate virus
dilution (in PBS containing 2 mM MgCl
 
2
 
) was dripped onto the cells,
and the plates were incubated at room temperature for 1 h. The virus-
containing medium was aspirated, and cells were cultured for 72 h un-
til use. To estimate infection efficiencies, COS-7, CHO, and MDCK
cells were infected with various concentrations of a recombinant ade-
novirus carrying the 
 
b
 
-galactosidase gene under the control of Rous
sarcoma virus promoter (25), as described above. 3 d after infection, cells
were fixed in PBS containing 0.05% glutardialdehyde, and 
 
b
 
-galac-
tosidase activity was detected by staining cells with 3 mM K
 
3
 
Fe(CN)
 
6
 
/3
mM K
 
4
 
Fe(CN)
 
6
 
/2 mM MgCl
 
2
 
/5-bromo-4-chloro-3-indolyl 
 
b
 
-
 
D
 
-galac-
toside (0.5 mg/ml) in Hepes buffer (pH 7.4). The percentage of blue
cells was determined from random fields, and at least 800 cells were
counted per plate.
 
Immunoprecipitation.
 
COS-7 cells were transfected with various
V2 receptor constructs as described above. About 18 h later, cells
were split into 6-well plates (5 
 
3
 
 10
 
5
 
 cells/well). On the following day,
transfected cells were incubated with [
 
35
 
S]methionine (0.5 mCi/ml in
culture medium; Dupont-NEN, Brussels, Belgium) for an additional
18 h. Cells were then washed twice with PBS and treated with 120 
 
m
 
l
lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM DTT, 1 mM
EDTA, 1% desoxycholate, 1% NP-40, 0.2 mM PMSF, 10 
 
m
 
g/ml apro-
tinin). After vigorous vortexing, followed by removal of cell debris by
centrifugation, 20 
 
m
 
g/ml of the anti–V2 receptor antibody was added
to the supernatants containing solubilized receptor protein. After in-
cubation of samples at 4
 
8
 
C for 2 h in constant rotation, 60 
 
m
 
l of 10%
(wt/vol) protein A–Sepharose beads (Sigma Chemical Co., Deisen-
hofen, Germany) was added, and samples were incubated overnight
at 4
 
8
 
C. Sepharose beads were pelleted (12,000 
 
g
 
, 3 min) and washed
twice with 1 ml washing buffer A (600 mM NaCl, 50 mM Tris-HCl,
pH 7.4, 0.1% Triton X-100, 1% NP-40) and twice with 1 ml washing
buffer B (300 mM NaCl, 10 mM EDTA, 100 mM Tris-HCl, pH 7.4).
Pellets were then boiled with 40 
 
m
 
l SDS sample buffer, and SDS-
PAGE (12.5%) was performed. Precipitated 
 
35
 
S-labeled membrane
proteins were visualized by autoradiography of the dried gels with
X-OMAT AR-5 film (Eastman Kodak Co., Rochester, NY).
 
ELISAs.
 
To estimate cell surface expression of receptors carry-
ing an amino-terminal HA-tag, we developed an indirect cellular
ELISA (9). Briefly, transfected COS-7 cells were seeded into 96-well
plates, fixed without disrupting the cell membrane, and incubated
with an anti-HA mAb (12CA5; Boehringer Mannheim, Mannheim,
Germany). Bound anti-HA antibody was then detected with the
help of a peroxidase-labeled anti–mouse IgG antibody (Sigma Chem-
ical Co.).
To further assess the association between amino- and carboxy-
terminal receptor fragments, the following sandwich ELISA was de-
veloped. 3 d after transfection, COS-7 cells were harvested, and cell
pellets were resuspended in lysis buffer (see above). Cell debris was
removed by centrifugation, and supernatants were used for ELISA
measurements. Microtiter plates were coated with a polyclonal rabbit
antibody directed against a peptide corresponding to the carboxy-ter-
minal 29 amino acids of the human V2 vasopressin receptor (5 
 
m
 
g/ml
in PBS; kindly provided by Dr. Paul Goldsmith, National Institutes of
Health, Bethesda, MD). After incubation for 16 h at 4
 
8
 
C, plates were
blocked with 10% FBS in PBS. Cell lysates were then applied and in-
cubated for 2 h at 37
 
8
 
C. Plates were washed three times with PBS
containing 0.05% Triton X-100 (PBS-T). The anti-HA mAb (12CA5;
1 
 
m
 
g/ml PBS-T) was then added, and plates were incubated for 2 h at
37
 
8
 
C. Plates were washed with PBS-T and incubated with a 1:3,000 di-
lution of a peroxidase-conjugated anti–mouse IgG antibody for 1 h at
37
 
8
 
C. After removal of excess unbound antibody, H
 
2
 
O
 
2
 
 and 
 
o
 
-phe-
nylenediamine (2.5 mM each in 0.1 M phosphate-citrate buffer, pH
5.0) were added to serve as substrate and chromogen, respectively.
After 15 min, the enzyme reaction (carried out at room temperature)
was stopped by the addition of 1 M H
 
2
 
SO
 
4
 
 containing 0.05 M Na
 
2
 
SO
 
3
 
,
and color development was measured bichromatically at 492 and 620 nm
using an ELISA reader (Titertek Multiskan MCC/340; Labsystems
Inc., Helsinki, Finland).
 
Functional assays.
 
Inositol phosphate and cAMP measurements
were performed as described previously (9, 10). For radioligand-bind-
ing studies, cells were harvested 72 h after transfection or infection,
and binding assays were performed using membrane homogenates.
Incubations were carried out for 1 h at 22
 
8
 
C in a 0.25-ml volume, with
16 nM [
 
3
 
H]AVP (64 Ci/mmol; Dupont-NEN). Nonspecific binding
was defined as binding in the presence of 5 
 
m
 
M AVP. The protein
content of samples was determined by the method of Bradford (26).
Binding data were analyzed by a nonlinear least squares curve-fitting
procedure using the computer program LIGAND (27).
 
mRNA preparation and reverse transcription followed by PCR
(RT-PCR).
 
G418-resistant CHO cell clones were screened for (mu-
tant) V2 receptor mRNA expression by RT-PCR. Cells (10
 
6
 
) were
washed twice with PBS, and mRNA was prepared using the Oligo-
tex
 
®
 
 direct mRNA kit (QIAGEN Inc., Hilden, Germany). First-
strand cDNA was synthesized by reverse transcriptase (Stratagene
Inc., Heidelberg, Germany) using an oligo-dT primer as recom-
mended. To estimate cDNA copy numbers, a competitive PCR was
performed according to a method described by Siebert and Larrick
(28). Thus, cDNA and an internal DNA standard (genomic V2 vaso-
pressin receptor in pcD-PS) were coamplified in the PCR experi-
ments. The resultant PCR products were electrophoresed, and ethid-
ium bromide–stained DNA bands were visualized under ultraviolet
(UV) light.
 
Immunofluorescence studies.
 
Immunofluorescence studies were
carried out to examine the subcellular distribution of wild-type and
mutant vasopressin V2 receptors. 1 d after infection of COS-7 or
MDCK cells (100 pfu/cell), cells were transferred into 6-well plates
containing sterilized glass coverslips. Approximately 48 h later, cells
were fixed and probed with a rabbit polyclonal antibody directed
against the carboxy terminus of the human V2 receptor as described
previously (10). Fluorescence images were obtained with a confocal
laser scanning microscope (model LCM 410; Carl Zeiss, Inc., Thorn-
wood, NY).
 
Results
 
Mechanism of functional rescue.
 
To test the hypothesis that the
ability of the V2-tail polypeptide to restore function to se-
lected mutant V2 vasopressin receptors is due to a direct asso-
ciation between the two polypeptides, a coimmunoprecip-
itation strategy was used. COS-7 cells were cotransfected with
plasmids coding for V2-tail and E242stop, labeled with
[
 
35
 
S]methionine, and immunoprecipitated proteins were sepa-
rated by SDS-PAGE. As shown in Fig. 2, the wild-type V2 re-
ceptor migrated as a broad band ranging from 38 to 43 kD,
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whereas the V2-tail polypeptide was detectable as a 14-kD
band. When the V2-tail fragment was coexpressed with the
E242stop truncation mutant, an additional band could be de-
tected at 
 
z
 
 29 kD. No specific bands were observed when the
E242stop construct was transfected alone or when COS-7 cells
expressing the wild-type V2 receptor or V2-tail were incubated
with a nonspecific antibody (rabbit anti–CCK
 
A
 
 receptor anti-
body, data not shown).
To further characterize the interaction of the V2-tail
polypeptide with the mutant V2 receptors, a novel sandwich
ELISA system was developed (Fig. 3 
 
A
 
). COS-7 cells trans-
fected with wild-type V2 receptor DNA (4 
 
m
 
g/dish) showed
high receptor expression levels of 
 
z
 
 500 fmol/mg protein, and
transfected wild-type receptor DNA (4–100 ng plasmid DNA)
as well as membrane lysates (1:10) had to be diluted for sand-
wich ELISA to correlate OD readings directly with B
 
max
 
 val-
ues (Fig. 3 
 
B
 
). For control purposes, cell lysates were also pre-
pared from COS-7 cells transfected with CCK
 
A
 
, GnRH, and
m3 muscarinic receptor constructs containing an amino-termi-
nal HA-tag. The epitope tags did not interfere with the proper
expression and function of these receptors (data not shown).
In all three cases, OD values were indistinguishable from
background values determined with lysis buffer alone (data
not shown). Similarly, membrane lysates prepared from COS-7
cells transfected with E242stop or V2-tail alone or mixed after
solubilization did not result in OD readings that were signifi-
cantly higher than background, even when the sandwich
ELISA was performed with undiluted membrane lysates (Ta-
ble I). However, a six- to sevenfold increase in OD readings
(compared to background values) was obtained when mem-
brane lysates prepared from cells cotransfected with E242stop
and V2-tail were assayed by sandwich ELISA, strongly sug-
gesting that the two polypeptides are directly associated with
each other. This interaction was no longer observed when
membrane lysates were heated to 80
 
8
 
C for 10 min (Table I).
Similar results were obtained by adding SDS (1% wt/vol) to
the membrane lysates, whereas SDS treatment of membrane
lysates from wild-type V2 receptor transfected cells had little
influence on OD readings in sandwich ELISA (data not
shown). Introduction of the Y280C point mutation (which
functionally inactivates the wild-type V2 receptor) into the V2-
tail polypeptide led to a mutant V2 receptor fragment (V2-
Y280C-tail) that retained the ability to associate efficiently
with the E242stop mutant receptor (see Table I). Similar re-
sults were obtained when various other mutations known to
functionally inactivate the wild-type V2 receptor (e.g., L292P
or V277del) were introduced into the V2-tail fragment (data
not shown). To further characterize the underlying mechanism
leading to functional reconstitution of nontruncated receptor
mutants, e.g., Y280C (10), the interaction of the V2-tail frag-
ment with Y280C was studied in the sandwich ELISA. There-
fore, the carboxy-terminal antibody recognition site was
removed from a receptor construct, referred to as Y280C-
R337stop, to allow interaction studies in the ELISA. Mem-
brane lysates from COS-7 cells cotransfected with Y280C-
R337stop and V2-tail plasmids showed increased OD values in
the test (see Table I). In another set of control experiments,
the V2-tail polypeptide was coexpressed with HA-tagged wild-
type m3 muscarinic receptor, and HA-tagged mutant GnRH
or m3 muscarinic receptors that were truncated in their third
intracellular loops in a fashion similar to the E242stop V2 mu-
tant receptor. As expected, membrane lysates prepared from
Figure 2. Immunopre-
cipitation of V2 recep-
tor constructs. COS-7 
cells were transfected 
with plasmids (4 mg to-
tal DNA/dish) coding 
for the wild-type V2
receptor (lane 1), 
E242stop and V2-tail 
(DNA ratio 1:1; lane 2), 
or V2-tail (lane 3) and 
incubated with [35S]me-
thionine for 18 h. Crude 
cell membranes were 
prepared and lysed. Im-
munoprecipitation (us-
ing an antibody directed against the carboxy-terminal portion of the 
V2 receptor) and SDS electrophoresis were performed as described 
in Methods. *Coprecipitated V2 receptor fragment, E242stop. One 
representative experiment out of three is shown.
Figure 3. Relationship 
between V2 vaso-
pressin receptor den-
sity and extinction de-
termined by sandwich 
ELISA. (A) Microtiter 
plates were coated with 
a polyclonal antibody 
directed against the car-
boxy-terminal portion 
of the V2 receptor (I). 
Solubilized HA-tagged 
receptor proteins (II) 
were caught by the car-
boxy-terminal antibody 
and detected using an 
HA-specific mAb (III), followed by incubation with a peroxidase-linked anti–mouse antibody (IV). (B) COS-7 cells were transfected with in-
creasing amounts of V2 (wt) receptor DNA (4–100 ng). For sandwich ELISA measurements, cells were harvested 72 h after transfection, and 
crude cell membranes were prepared. Membranes or lysates were used for [3H]AVP saturation-binding assays or sandwich ELISA. ELISA and 
radioligand-binding studies were carried out as described in Methods. Data are given as means6SEM of two independent experiments, each car-
ried out in duplicate (binding assay) or triplicate (ELISA).
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these cells did not give specific OD readings in the sandwich
ELISA (see Table I), demonstrating that the V2-tail fragment
interacted with the E242stop V2 mutant receptor with high
specificity.
 
Coexpression of the V2-tail polypeptide with other GPCRs.
 
Next, we wanted to show that overexpression of the V2-tail
polypeptide does not interfere with the function of other
GPCRs. Toward this goal, COS-7 cells were cotransfected
with plasmids coding for the V2-tail fragment and several
other GPCRs such as the V1a vasopressin, Ox, GnRH, CCK
 
A
 
,
or LH receptors.
As shown in Table II, the coexpressed V2-tail polypeptide
had no significant effect on the potency and efficacy of second
messenger responses mediated by the different receptors, sug-
gesting that even high levels of the V2-tail polypeptide (as ob-
served in transiently transfected COS-7 cells) did not interfere
with the function of other GPCRs.
 
Characterization of CHO cell lines stably expressing wild-
type and mutant V2 receptors.
 
To establish a cellular model
system that would closely mimic the physiological situation of
receptor expression levels, stable CHO cell lines were created
by cotransfection of the wild-type or various mutant V2 vaso-
pressin receptors (E242stop, Y280C, and W284stop) and pcDNA-
neo. Several G418-resistant cell lines were screened for receptor
expression by radioligand-binding, functional, or immunologi-
cal techniques. Cell lines transfected with the wild-type V2 re-
ceptor gene were functionally screened by measuring AVP-
induced increases in intracellular cAMP levels. Two cell clones,
V2-1 and V2-2, that differed in the magnitude of AVP-induced
cAMP responses (Table III) were maintained for further ex-
periments. [
 
3
 
H]AVP radioligand-binding studies showed that
the CHO–V2-1 cell clone expressed 
 
z
 
 21 fmol receptor pro-
tein per milligram of membrane protein, whereas the CHO–
V2-2 cell clone did not show any specific [
 
3
 
H]AVP binding ac-
tivity, apparently due to a very low level of receptor expression
(see Table III).
Since the mutant V2 receptors used in this study were un-
able to bind radioligand or to induce a second messenger re-
sponse (10), CHO cell clones transfected with the different
mutant V2 receptor constructs were screened initially by im-
munological techniques based on the detection of the amino-
terminal HA-tag. First, we attempted to screen stable cell lines
by using a previously developed indirect cellular ELISA sys-
tem (9). Unfortunately, none of the cell clones showed any de-
 
Table I. Fragment Association Determined by
Sandwich ELISA
 
Construct OD
 
492 nm
 
Wild-type V2/vector (1:2) 1.275
 
6
 
0.010
E242stop 0.154
 
6
 
0.003
V2-tail 0.141
 
6
 
0.002
E242stop 
 
1
 
 V2-tail (mixed after solubilization) 0.143
 
6
 
0.002
E242stop 
 
1
 
 V2-tail (cotransfected) 1.006
 
6
 
0.015
E242stop 
 
1
 
 V2-tail (cotransfected 
 
1
 
 heating) 0.089
 
6
 
0.001
E242stop 1 V2-Y280C-tail (cotransfected) 0.97860.036
Y280C-R337stop 1 V2-tail (cotransfected) 0.87860.047
Wild-type m3 1 V2-tail (cotransfected) 0.14260.005
m3-S318stop 1 V2-tail (cotransfected) 0.13760.001
GnRH-L285stop 1 V2-tail (cotransfected) 0.14860.003
Membrane lysates prepared from COS-7 cells transfected with E242stop
or V2-tail alone (4 mg plasmid DNA/dish) or mixed after solubilization
were tested in a sandwich ELISA (OD 492 nm). To detect fragment as-
sociation, the truncated V2 receptor (E242stop) was cotransfected
with V2-tail or V2-Y280C-tail. Additionally, lysates of cotransfected
E242stop/V2-tail (DNA ratio 1:1; 4 mg total plasmid DNA/dish) were
incubated at 80°C for 10 min and then tested in ELISA. HA-tagged m3
muscarinic receptor or truncated GnRH (GnRH-L285stop) or m3 mus-
carinic (m3-S318stop) receptors were cotransfected with V2-tail to eval-
uate the specificity of fragment association. Data are given as
means6SEM of two independent experiments, each performed in tripli-
cate.
Table II. Functional Activity of Various G Protein–coupled Receptors Coexpressed with the V2-Tail Fragment
IP cAMP
Transfected construct(s) Maximum increase in IP levels Agonist EC50 Maximum increase in cAMP levels Agonist EC50
-Fold above basal nM -Fold above basal nM
V1a-R 4.1 0.4660.11 —* —
V1a-R/V2-tail 5.2 0.7660.09 — —
Ox-R 2.9 3.660.1 — —
Ox-R/V2-tail 2.3 3.160.4 — —
GnRH-R 4.4 3.160.1 — —
GnRH-R/V2-tail 5.1 3.960.7 — —
CCKA-R 4.6 3.761.6 — —
CCKA-R/V2-tail 3.6 3.960.3 — —
LH-R 1.8 n.d. 5.8 0.2560.02
LH-R/V2-tail 2.0 n.d. 4.8 0.0960.01
COS-7 cells were cotransfected with V2-tail (2 mg plasmid DNA/dish) or vector DNA (2 mg pcD-PS/dish as control, to keep the amount of DNA con-
stant at 4 mg/dish) and different G protein–coupled receptors ( 2 mg plasmid DNA/dish; R, receptor). Functional assays were carried out as described
in Methods. Transfected cells were stimulated with the appropriate agonists (AVP, Ox, GnRH, sulfated CCK 8, and human chorionic gonadotropin,
respectively). EC50 and Emax values were obtained from agonist concentration–response curves, using the computer program GraphPad Prism. Data
are given as means6SEM of two or three independent experiments, each carried out in duplicate. n.d., not determinable with sufficient accuracy. IP,
inositol phosphate. *No significant increase in cAMP above basal levels.
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tectable cell-surface expression (detection limit of the ELISA
system 5 40 fmol/mg protein; data not shown). We next tried
to determine receptor levels in stable cell lines from total cell
extracts by sandwich ELISA. Since many mutant receptor pro-
teins are retained in the cell interior (29), this ELISA was ex-
pected to be more sensitive than a cell-surface ELISA. Consis-
tent with this notion, the sandwich ELISA was able to detect
receptor levels as low as 10 fmol/mg protein (Fig. 3 B). How-
ever, it should be noted that only full-length V2 receptor con-
structs in which both epitopes are present can be detected by
sandwich ELISA. Lysates from the CHO clones V2-1 and
Y280C gave OD values corresponding to Bmax values of z 14
and 9 fmol/mg, respectively.
To detect expression of mutant V2 receptor mRNA in the
various G418-resistant cell lines, RT-PCR analysis was used
(Fig. 4 A). Primers were chosen so that the sizes of amplified
PCR products would be characteristic for individual receptors.
V2 receptor mRNA was found in all cell lines investigated, and
PCR products obtained with the truncated V2 receptors were
distinguishable by their smaller size (406 bp for E242stop and
532 bp for W284stop). To be able to compare receptor mRNA
levels in different CHO cell lines, a competitive PCR strategy
was used (28). cDNAs resulting from RT were coamplified
with a standard dilution series of a plasmid containing genomic
V2 receptor sequence (genomic V2-pcD-PS). Primers were
chosen to flank a small 106-bp intron (present at amino acid
codon 304) in the V2 receptor gene. To ensure accurate ampli-
fication of cDNA species, we first performed competitive PCR
on known amounts of mutant V2-Y280C plasmid DNA. It can
be seen in Fig. 4 B that the intensity of the resultant Y280C
PCR product (638 bp) decreased in the presence of increasing
amounts of competitor DNA. In lanes where the two PCR
products show similar intensity, standard DNA and probe
DNA are thought to be present at similar copy numbers. Since
the number of cells used for mRNA preparation and the abso-
lute amount of added standard DNA are known, the number
of mRNA molecules present in a single cell can be estimated.
This method somewhat underestimates absolute mRNA lev-
els, because mRNA preparation and RT reaction are usually
not quantitative. Using identical cell numbers from stably
transfected CHO cell lines for mRNA preparation, and assum-
ing similar efficiencies of the RT reactions, this method should
allow a reasonable comparison of relative receptor mRNA
levels present in the different CHO cell clones. Thus, V2-1,
E242stop, W284stop, and Y280C cell clones were found to
express similar levels of V2 (wild-type or mutant) mRNA
(z 200–300 molecules/cell; n 5 2–3). As expected from func-
tional and radioligand-binding assays, mRNA levels in clone
V2-2 were estimated to be significantly lower (z 70 molecules/
cell).
Functional rescue of mutant V2 receptors by adenovirus-
mediated gene transfer. We next wanted to examine whether
the various CHO cell lines expressing low amounts of mutant
V2 receptors would gain the ability to mediate AVP-depen-
dent increases in cAMP levels in the presence of the V2-tail
Table III. Functional Characterization of CHO Cell Lines 
Stably Expressing Wild-Type or Mutant V2 Receptors after 
Infection with Ad-V2-Tail
Cell clones
AVP binding cAMP
Bmax
Maximum increase
in cAMP levels AVP EC50
fmol/mg protein -Fold above basal pM
V2-1 21.462.6 15.4 74620
V2-1 1 Ad-V2-tail n.d. 17.5 136630
V2-1 1 Ad-bGal n.d. 13.2 8567.6
V2-2 — 5.6 164629
E242stop 1 Ad-bGal — — —
E242stop 1 Ad-V2-tail — 3.9 133616
Y280C 1 Ad-bGal — — —
Y280C 1 Ad-V2-tail — 3.4 97622
W284stop 1 Ad-bGal — — —
W284stop 1 Ad-V2-tail — 4.7 129612
Stable CHO cell lines expressing wild-type or mutant V2 receptors were
tested in radioligand-binding and cAMP assays as described in Methods.
CHO clones expressing mutant V2 receptors did not show any specific
radioligand-binding activity or increases in cAMP production after stim-
ulation with 100 nM AVP. CHO cells were infected with Ad-V2-tail
(1,000 pfu/cell) and assayed 3 d after infection. Data are given as
means6SEM of two (binding assay) or three (cAMP assay) indepen-
dent experiments, each carried out in duplicate. n.d., not determined.
Figure 4. PCR-based analysis of mRNA expression in CHO cells sta-
bly transfected with mutant vasopressin receptors. (A) RT-PCR anal-
ysis was performed using mRNA isolated from CHO cell lines stably 
expressing wild-type and mutant V2 vasopressin receptors as de-
scribed in Methods. A pair of V2 receptor–specific primers was used 
(see Methods). PCR products were separated on a 1.5% agarose gel 
and stained with ethidium bromide (lanes 1 and 6: 1-kb standard). 
The following cell clones were analyzed: V2-2 (lane 2), E242stop 
(lane 3), W284stop (lane 4), and Y280C (lane 5). (B) PCR reactions 
were carried out with a constant amount of Y280C cDNA (3 3 107 
molecules) in the presence of varying amounts of genomic V2-
pcD-PS as a competing DNA template. Lanes 1–12 correspond to 
geometric dilutions of genomic V2-pcD-PS, starting at 2 3 109 mole-
cules.
Rescue of Mutant V2 Receptors by Adenovirus-mediated Gene Transfer 1553
polypeptide. Given the potential therapeutic importance of
these rescue experiments, the V2-tail gene fragment was deliv-
ered to the various CHO cell lines using a recombinant ade-
novirus. To generate recombinant adenovirus vectors, we used
a strategy based on plasmid pJM17, which contains all essen-
tial adenovirus sequences required to produce infectious virus
upon transfection of HEK 293 cells (21). The resulting viruses
(Ad-V2 and Ad-V2-tail) carried the foreign expression cas-
sette inserted into the E1 region (Fig. 1 C).
To test the efficacy of adenovirus-mediated gene transfer,
we first infected COS-7 cells with Ad-V2. 3 d after infection
(25 pfu/cell), cells showed an eightfold AVP-induced (100 nM)
increase in intracellular cAMP levels. Additionally, COS-7
cells that had been transiently transfected with the E242stop
mutant receptor were infected with Ad-V2-tail (25 pfu/cell). 3 d
after infection, these cells, when incubated with 100 nM AVP,
showed a threefold increase in cAMP levels. Moreover, adeno-
virus-mediated gene transfer was also verified by immunocy-
tochemical techniques. As shown in Fig. 5, A and B, COS-7 cells
infected with Ad-V2 or Ad-V2-tail showed an intense staining
of cellular membranes when probed with an anti–V2 vaso-
pressin receptor antibody.
Based on these results, the various CHO cell lines stably
expressing low levels of mutant V2 receptors (E242stop,
Y280C, and W284stop) were incubated with increasing
amounts of Ad-V2-tail virus (Fig. 6 A). After infection with
Ad-V2-tail and stimulation with AVP, these CHO cell lines
gained the ability to mediate 3.4–4.7-fold increases in intracel-
lular cAMP levels (Table III, Fig. 6 B). These responses were
characterized by remarkably high AVP potencies (EC50 5 97–
133 pM; wild-type V2 receptor EC50 5 74–164 pM). However,
in order to observe these responses, relatively high virus con-
centrations had to be applied. Using an Ad-V2-tail virus con-
centration of 1,000 pfu/cell (the maximal titer of our purified
virus stock was 5 3 1010 pfu/ml), AVP-induced maximum
cAMP responses still showed a sharp increase, indicating that
the virus concentration was the limiting factor in the efficacy of
functional rescue (Fig. 6 A). To further address the question,
we determined infection efficiencies by incubating nontrans-
fected CHO cells with an adenovirus carrying the b-galactosi-
dase gene (1,000 pfu Ad-bGal/cell). 3 d after infection, only
27% of the total cell population showed positive nuclear stain-
ing after incubation with X-Gal. Stepwise dilution of Ad-bGal
(300 and 100 pfu/cell) further reduced the percentage of in-
fected cells to 13 and 4%, respectively. This result indicated
that adenovirus-mediated gene transfer is considerably less ef-
ficient in CHO than in COS-7 cells, where 93% of all cells can
be infected when 300 pfu/cell of Ad-bGal is applied. Addition-
ally, we used competitive RT-PCR to determine V2-tail
mRNA levels in CHO cells 3 d after infection with Ad-V2-tail
(1,000 pfu/cell). These experiments suggested that z 100 V2-
tail mRNA molecules are present per cell. Therefore, given an
infection efficiency of z 30% (see above), 300–400 mRNA
molecules appear to be present per infected CHO cell.
In a set of control experiments, we infected CHO–V2-1 cell
line with Ad-V2-tail or Ad-bGal. The maximal cAMP re-
sponse to AVP administration and the EC50 values were un-
changed, indicating that adenoviral infection itself had no sig-
Figure 5. Expression of wild-type V2 re-
ceptor and V2-tail polypeptide in COS-7 
and MDCK cells after adenovirus-medi-
ated gene transfer. COS-7 (A and B) and 
MDCK cells (C and D) were infected 
with Ad-V2 (A and C) and Ad-V2-tail (B 
and D) (100 pfu/cell), respectively. Im-
munofluorescence studies were carried 
out with permeabilized cells grown on 
glass coverslips, as described in Methods. 
Cells were treated with a rabbit poly-
clonal antibody directed against the car-
boxy-terminus of the human V2 receptor 
and then incubated with an FITC-linked 
goat anti–rabbit IgG secondary antibody. 
Fluorescence images were obtained with 
a confocal laser scanning microscope. 
Each picture is representative of at least 
two independent experiments.
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nificant effect on V2 receptor function (see Table III). On the
other hand, infection of CHO cell lines expressing the differ-
ent mutant V2 receptors with Ad-bGal did not result in a gain
in receptor function (see Table III).
Adenovirus-mediated gene transfer into a renal tubular cell
line. We next wanted to demonstrate that the two recombi-
nant adenovirus vectors, Ad-V2 and Ad-V2-tail, can also be
used to infect renal tubular cells. For these experiments, the
dog renal tubular cell line (MDCK) was used. Immunocy-
tochemical studies proved to be too insensitive to detect the
presence of endogenous V2 vasopressin receptor protein in
this cell line (data not shown). However, a weak but highly re-
producible increase in cAMP levels (1.5-fold over basal) was
demonstrated after administration of 100 nM AVP, suggesting
the presence of very low levels of endogenous V2 receptors.
After these initial experiments, MDCK cells were infected
with Ad-V2 (100 pfu/cell), and cAMP assays were performed
3 d later. We found that incubation of infected cells with 100 nM
AVP resulted in a 9.4-fold increase in cAMP levels. Consistent
with this result, studies with the recombinant Ad-bGal virus
(300 pfu/cell) indicated that MDCK cells can be infected with
rather high efficiency (z 75%). In addition, immunocy-
tochemical studies showed intense staining of cellular mem-
branes in MDCK cells infected with the Ad-V2 or Ad-V2-tail
virus (Fig. 5, C and D); however, fluorescence signals were
slightly weaker than those seen in COS-7 cells.
Discussion
Inactivating mutations in distinct GPCRs have been identified
as the cause of an ever-growing number of human diseases (6).
For example, numerous mutations (which include missense,
nonsense, deletion, or frameshift mutations) have been found
in the human V2 vasopressin receptor that are responsible for
the X-linked form of NDI. As a result, the encoded mutant re-
ceptors are impaired in their ability to bind ligands and/or to
couple to G proteins; in addition, it has been shown that many
of these mutant receptors are not properly trafficked to the
cell surface (29). From a therapeutic point of view, it would be
highly desirable to devise strategies that can restore function
to mutationally inactivated GPCRs. Based on the previous ob-
servation that GPCRs are assembled from multiple autono-
mous folding domains (8, 9), we speculated that it might be
possible to functionally rescue mutant GPCRs by supplying
the receptor fragment that is misfolded or lacking in the mu-
tant receptor(s). Indeed, we demonstrated recently in tran-
siently transfected COS-7 cells that selected mutant V2 recep-
tors containing mutations in the carboxy-terminal third of the
receptor protein regained considerable functional activity
when coexpressed with a V2-tail spanning the region where
the various mutations occurred (10).
One important goal of this study was to investigate by
which molecular mechanism the coexpressed V2-tail polypep-
tide can restore function to mutationally inactivated V2 recep-
tors. Since we could rule out the possibility of homologous
recombination at the plasmid level, as seen in the immunopre-
cipitation studies (see Fig. 2) and using a V2-tail construct
lacking the initiating ATG translation start codon (10), we
considered it likely that the V2-tail fragment directly associ-
ates with the mutant V2 receptor(s); however, direct evidence
was lacking. To test this hypothesis, two different experimental
strategies, a sandwich ELISA and a coimmunoprecipitation
protocol, were used. Using the E242stop mutant V2 receptor
as a model system, we could indeed demonstrate a direct inter-
action of the V2-tail polypeptide with the mutant V2 receptor.
Treatment with SDS or heating of cell lysates to 808C resulted
in the dissociation of the E242stop–V2-tail complex, indicating
that complex formation is driven by noncovalent interactions,
most likely by helix–helix packing. It is possible that molecular
chaperones that are likely to assist folding of the wild-type re-
ceptor proteins may also play a role in facilitating complex
(E242stop–V2-tail) formation. Consistent with this notion, we
have been unable to assemble functional V2 receptor proteins
Figure 6. Functional rescue of mutant V2 receptors stably expressed 
in CHO cells by adenovirus-mediated gene transfer. (A) CHO cell 
lines stably expressing different V2 mutant receptors were infected 
with various amounts of Ad-V2-tail virus, and AVP-induced (100 
nM) increases in cAMP levels were determined as described in Meth-
ods. Responses are expressed as fold increase in cAMP content above 
basal levels (122615 cpm) determined in the absence of AVP. (B) To 
estimate EC50 values, the different CHO cell lines were infected with 
1,000 pfu/cell of Ad-V2-tail virus and incubated with increasing con-
centrations of AVP. Data are presented as means6SEM of two inde-
pendent experiments, each carried out in duplicate. Cell clone V2-2 
(s), E242stop (j), W284stop (d), and Y280C (h).
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from solubilized receptor fragments in vitro. Interestingly, it
has been shown recently that chaperone-dependent mecha-
nisms are essential for proper folding of rhodopsin and most
likely other GPCRs (30, 31). However, the identity of the
chaperones required for the proper folding of GPCRs that are
different from rhodopsin remains to be elucidated.
Sandwich ELISA studies also showed that introduction of
various mutations (Y280C, L292P, and V277del, all located in
the sixth transmembrane helix) into the V2-tail polypeptide
did not interfere with the ability of the polypeptide to form a
complex with the E242stop V2 mutant receptor, indicating
that these mutations do not exert a very dramatic effect on re-
ceptor assembly. Since the full-length V2 receptors containing
these mutations can no longer bind ligands and couple to G
proteins (10), it appears likely that these point mutations
(Y280C, L292P) and the triplet deletion (V277del) in the sixth
transmembrane helix result in minor conformational changes,
causing the functional inactivation of the mutant V2 receptor
protein. The observed ability of the V2-tail fragment to inter-
act with different mutant V2 receptors is consistent with sev-
eral recent reports suggesting that GPCRs can form dimers.
Using chimeric a2-adrenergic/m3 muscarinic receptors, Mag-
gio et al. (32) demonstrated that chimeric receptors can com-
plement each other functionally. Also, receptor dimerization
can explain the reconstitution of binding activity after coex-
pression of two binding-defective point mutants of the angio-
tensin II type 1 receptor (33). Finally, Bouvier and co-workers
(34) recently used a double epitope tagging approach to di-
rectly demonstrate dimer formation of the b2-adrenergic re-
ceptor in transiently and stably transfected cells.
By taking advantage of sandwich ELISA and the ability of
complementary V2 receptor fragments to form functional re-
ceptor complexes, it should be possible to screen a large num-
ber of V2 receptor mutations for their ability to interfere with
proper receptor assembly. Such studies are likely to lead to the
identification of critical interhelical contact sites, and may
therefore provide novel insights into the molecular architec-
ture of the transmembrane core of GPCRs.
To verify that the V2-tail fragment does not interfere with
the function of other GPCRs, the V2-tail polypeptide was co-
expressed in COS-7 cells with wild-type V1a vasopressin, Ox,
GnRH, CCKA, and LH receptors. We found that the coex-
pressed V2-tail polypeptide had no significant effect on the
functional responses mediated by the different wild-type re-
ceptors and was unable to form complexes with truncated m3
muscarinic or GnRH receptors. This observation suggests that
the interaction of the V2-tail fragment with mutant V2 recep-
tors is characterized by a very high degree of specificity. Based
on this finding, it is likely that delivery of the V2-tail polypep-
tide (or analogous peptides derived from other GPCRs) to the
kidney will lead to functional effects only in those cells where
the V2 receptor is physiologically expressed. In contrast, im-
proper targeting of a viral vector encoding the wild-type V2 re-
ceptor might result in serious side effects, particularly since
AVP can reach virtually every body cell via the blood stream.
Since transfection of COS-7 cells is known to lead to very
high levels of protein expression in only a small subset of cells
with receptor densities estimated to be 10–100 times higher
than those found in native tissues, another major goal of this
study was to show that this coexpression approach can also be
successfully applied when the mutant receptors are expressed
at rather low (physiological) levels. Towards this aim, we es-
tablished CHO cell lines stably expressing low levels of three
different mutant V2 vasopressin receptors, E242stop, Y280C,
and W284stop. Gene transfer methods used in cell culture are
usually inefficient or impractical in vivo. However, recombi-
nant adenoviruses have been used successfully to introduce
foreign genes into a great variety of physiological tissues and
cell types, including cultured renal cells (35) and renal tubular
cells in vivo (36). Therefore, given the potential therapeutic
usefulness of the described coexpression strategy, we con-
structed two replication-deficient recombinant adenoviruses
coding for the wild-type V2 receptor and the V2-tail polypep-
tide, resulting in Ad-V2 and Ad-V2-tail, respectively. Whereas
none of the CHO cell lines expressing low levels of mutant V2
receptors (E242stop, Y280C, or W284stop) was able to medi-
ate a significant increase in intracellular cAMP levels upon in-
cubation with AVP, a pronounced cAMP response was re-
stored after infection with the Ad-V2-tail virus. The observed
AVP concentration–response curves were characterized by
EC50 values very similar to the corresponding wild-type recep-
tor values (70–160 pM). However, maximal cAMP responses
were approximately fourfold reduced compared to a CHO cell
line expressing the wild-type V2 receptor at similar levels
(judged by estimating receptor mRNA levels). One possible
reason for the reduced degree of functional rescue seen in
CHO compared to COS-7 cells (10) could be that the Ad-V2-
tail virus infected only a subpopulation of the mutant recep-
tor–expressing CHO cells, whereas the wild-type V2 receptor
is present in all cells of the stable CHO cell line studied. To
test this hypothesis, we examined the ability of CHO cells to
be infected by Ad-bGal, a recombinant adenovirus vector cod-
ing for bacterial b-galactosidase. Surprisingly, these studies
showed that adenoviral infection of fibroblast-like CHO cells
was much less efficient (, 30% using 1,000 pfu Ad-bGal/cell)
than previously reported for rodent epithelium cells (11, 33) or
found with monkey (COS-7) or dog (MDCK) renal epithelial
cells. Therefore, given the fact that the Ad-V2-tail virus is
likely to infect , 30% of CHO cells expressing mutant V2 re-
ceptors, the observed degree of functional rescue appears
quite remarkable. Another important point was to demon-
strate that the Ad-V2-tail and Ad-V2 viruses can also infect re-
nal epithelial cells where the V2 vasopressin receptor is physi-
ologically expressed. For these experiments, the dog renal
tubular cell line, MDCK, was used. We showed that MDCK
cells could be infected efficiently by the Ad-V2-tail and Ad-V2
viruses. The two viruses directed the expression of high levels
of V2 receptor protein and the V2-tail fragment, as shown by
immunocytochemical techniques. Both polypeptides showed a
similar subcellular distribution, characterized by the staining
of intracellular membranes (endoplasmic reticulum–Golgi
complex) and the plasma membrane. In addition, MDCK cells
infected with Ad-V2 showed a dramatic increase in intracellu-
lar cAMP levels after the addition of AVP.
The findings described here may be relevant not only for
other members of the GPCR family but also for polytopic inte-
gral membrane proteins in general. It has been demonstrated
for example, that many proteins that contain multiple mem-
brane-spanning domains can be assembled from two or more
protein fragments. These proteins include sodium channels
(37), the a-factor transporter in yeast (38), adenylyl cyclases
(39), and lactose permease (40, 41). Based on the subunit char-
acter of integral membrane proteins, the rescue strategy de-
scribed here for mutant V2 vasopressin receptors may also be
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applicable to other classes of (mutant) membrane proteins that
may play a role in human disease.
In conclusion, using mutant V2 vasopressin receptors as a
model system, we demonstrated that mutationally inactivated
GPCRs can be functionally rescued via adenovirus-mediated
gene transfer of a carboxy-terminal receptor fragment. Based
on the efficiency and specificity of the observed rescue phe-
nomenon, the application of this approach for gene therapy
purposes appears promising. Therefore, it should be of consid-
erable interest to study the feasibility of this novel therapeutic
strategy in a transgenic animal model.
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